Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.

Autor:	Kumar A; Memorial Sloan Kettering Cancer Center, New York, NY., Casulo C; Wilmot Cancer Institute, University of Rochester, Rochester, NY., Advani RH; Stanford Cancer Institute, Stanford University, Stanford, CA., Budde E; City of Hope National Medical Center, Duarte, CA., Barr PM; Wilmot Cancer Institute, University of Rochester, Rochester, NY., Batlevi CL; Memorial Sloan Kettering Cancer Center, New York, NY., Caron P; Memorial Sloan Kettering Cancer Center, New York, NY., Constine LS; Wilmot Cancer Institute, University of Rochester, Rochester, NY., Dandapani SV; City of Hope National Medical Center, Duarte, CA., Drill E; Memorial Sloan Kettering Cancer Center, New York, NY., Drullinsky P; Memorial Sloan Kettering Cancer Center, New York, NY., Friedberg JW; Wilmot Cancer Institute, University of Rochester, Rochester, NY., Grieve C; Memorial Sloan Kettering Cancer Center, New York, NY., Hamilton A; Memorial Sloan Kettering Cancer Center, New York, NY., Hamlin PA; Memorial Sloan Kettering Cancer Center, New York, NY., Hoppe RT; Stanford Cancer Institute, Stanford University, Stanford, CA., Horwitz SM; Memorial Sloan Kettering Cancer Center, New York, NY., Joseph A; Memorial Sloan Kettering Cancer Center, New York, NY., Khan N; Memorial Sloan Kettering Cancer Center, New York, NY., Laraque L; Memorial Sloan Kettering Cancer Center, New York, NY., Matasar MJ; Memorial Sloan Kettering Cancer Center, New York, NY., Moskowitz AJ; Memorial Sloan Kettering Cancer Center, New York, NY., Noy A; Memorial Sloan Kettering Cancer Center, New York, NY., Palomba ML; Memorial Sloan Kettering Cancer Center, New York, NY., Schöder H; Memorial Sloan Kettering Cancer Center, New York, NY., Straus DJ; Memorial Sloan Kettering Cancer Center, New York, NY., Vemuri S; Memorial Sloan Kettering Cancer Center, New York, NY., Yang J; University of California San Francisco, San Francisco, CA., Younes A; AstraZeneca US, Wilmington, DE., Zelenetz AD; Memorial Sloan Kettering Cancer Center, New York, NY., Yahalom J; Memorial Sloan Kettering Cancer Center, New York, NY., Moskowitz CH; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Jul 10; Vol. 39 (20), pp. 2257-2265. Date of Electronic Publication: 2021 Apr 28.
DOI:	10.1200/JCO.21.00108
Abstrakt:	Purpose: To improve curability and limit long-term adverse effects for newly diagnosed early-stage (ES), unfavorable-risk Hodgkin lymphoma. Methods: In this multicenter study with four sequential cohorts, patients received four cycles of brentuximab vedotin (BV) and doxorubicin, vinblastine, and dacarbazine (AVD). If positron emission tomography (PET)-4-negative, patients received 30-Gy involved-site radiotherapy in cohort 1, 20-Gy involved-site radiotherapy in cohort 2, 30-Gy consolidation-volume radiotherapy in cohort 3, and no radiotherapy in cohort 4. Eligible patients had ES, unfavorable-risk disease. Bulk disease defined by Memorial Sloan Kettering criteria (> 7 cm in maximal transverse or coronal diameter on computed tomography) was not required for cohorts 1 and 2 but was for cohorts 3 and 4. The primary end point was to evaluate safety for cohort 1 and to evaluate complete response rate by PET for cohorts 2-4. Results: Of the 117 patients enrolled, 116 completed chemotherapy, with the median age of 32 years: 50% men, 98% stage II, 86% Memorial Sloan Kettering-defined disease bulk, 27% traditional bulk (> 10 cm), 52% elevated erythrocyte sedimentation rate, 21% extranodal involvement, and 56% > 2 involved lymph node sites. The complete response rate in cohorts 1-4 was 93%, 100%, 93%, and 97%, respectively. With median follow-up of 3.8 years (5.9, 4.5, 2.5, and 2.2 years for cohorts 1-4), the overall 2-year progression-free and overall survival were 94% and 99%, respectively. In cohorts 1-4, the 2-year progression-free survival was 93%, 97%, 90%, and 97%, respectively. Adverse events included neutropenia (44%), febrile neutropenia (8%), and peripheral neuropathy (54%), which was largely reversible. Conclusion: BV + AVD × four cycles is a highly active and well-tolerated treatment program for ES, unfavorable-risk Hodgkin lymphoma, including bulky disease. The efficacy of BV + AVD supports the safe reduction or elimination of consolidative radiation among PET-4-negative patients. Competing Interests: Anita KumarStock and Other Ownership Interests: BridgebioConsulting or Advisory Role: Celgene, Kite, a Gilead company, AstraZenecaResearch Funding: AbbVie/Genentech, Adaptive Biotechnologies, Celgene, Seattle Genetics, AstraZeneca, Pharmacyclics Carla CasuloHonoraria: Gilead SciencesResearch Funding: Celgene, Verastem, Gilead SciencesTravel, Accommodations, Expenses: Gilead Sciences, Roche Ranjana H. AdvaniConsulting or Advisory Role: Genentech/Roche, Seattle Genetics, Takeda, Portola Pharmaceuticals, Celgene, Sanofi, Kura Oncology, Merck, Karyopharm Therapeutics, ADC Therapeutics, Daiichi Sankyo, Bristol Myers Squibb/Celgene, Epizyme, IncyteResearch Funding: Millennium, Seattle Genetics, Genentech/Roche, Pharmacyclics, Janssen, Merck, Kura Oncology, Regeneron, Forty Seven, Cyteir Elizabeth BuddeHonoraria: AstraZenecaConsulting or Advisory Role: Roche/Genentech, Kite/Gilead, NovartisSpeakers' Bureau: Kite, a Gilead company, AstraZenecaResearch Funding: Merck, Amgen, MustangBio, AstraZenecaPatents, Royalties, Other Intellectual Property: CCR4 CAR T cells for treatment of patients with CCR4 positive cancer, CD33CAR for treatment of patients with CD33+ acute myeloid leukemiaTravel, Accommodations, Expenses: Roche/Genentech, Kite/Gilead, AstraZeneca Paul M. BarrConsulting or Advisory Role: Pharmacyclics, AbbVie, Seattle Genetics, Genentech, Novartis, Infinity Pharmaceuticals, Janssen, Merck, TG Therapeutics, MorphoSys, AstraZeneca, BeiGene, MEI Pharma, Bristol Myers Squibb/Celgene, BayerResearch Funding: Pharmacyclics, AstraZeneca Connie L. BatleviStock and Other Ownership Interests: Moderna Therapeutics, Novavax, Pfizer, Bristol Myers Squibb, Regeneron, ViatrisHonoraria: DAVAOncologyConsulting or Advisory Role: Lifesci Capital, GLG, Juno Therapeutics, Celgene, Seattle Genetics, Kite, a Gilead company, TG Therapeutics, Karyopharm TherapeuticsResearch Funding: Janssen Biotech, Novartis, Epizyme, Xynomic Pharma, Bayer, Roche, AutolusOpen Payments Link: https://openpaymentsdata.cms.gov/physician/2778694 Philip CaronStock and Other Ownership Interests: AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson/Janssen, Novartis, Pfizer, Teva Louis S. ConstineHonoraria: UpToDate, Springer, Lippincott Savita V. DandapaniResearch Funding: Bayer Pamela DrullinskyResearch Funding: Novartis Jonathan W. FriedbergConsulting or Advisory Role: Astellas Pharma, NovartisResearch Funding: Seattle GeneticsPatents, Royalties, Other Intellectual Property: Patent on bone marrow microenvironment signals Paul A. HamlinConsulting or Advisory Role: Juno Therapeutics, Karyopharm Therapeutics, Celgene, Sandoz, AstraZeneca/MerckResearch Funding: Spectrum Pharmaceuticals, Seattle Genetics, Janssen, Portola Pharmaceuticals, GlaxoSmithKline, Molecular Templates, Incyte Richard T. HoppeStock and Other Ownership Interests: Johnson & Johnson, Pfizer Steven M. HorwitzConsulting or Advisory Role: Celgene, Millennium, Kyowa Hakko Kirin, Seattle Genetics, ADC Therapeutics, Portola Pharmaceuticals, Verastem, Takeda, Astex Pharmaceuticals, Kura Oncology, Acrotech Biopharma, C4 Therapeutics, Janssen Oncology, Trillium Therapeutics, Vividion Therapeutics, Myeloid Therapeutics, Ono PharmaceuticalResearch Funding: Celgene, Seattle Genetics, Takeda, Kyowa Hakko Kirin, Aileron Therapeutics, ADC Therapeutics, Verastem, Forty Seven, Trillium Therapeutics, Daiichi Sankyo, Affimed Therapeutics, Corvus Pharmaceuticals Niloufer KhanResearch Funding: Seattle Genetics Matthew J. MatasarStock and Other Ownership Interests: MerckHonoraria: Genentech, Roche, GlaxoSmithKline, Bayer, Pharmacyclics, Janssen, Seattle Genetics, Takeda, IGM Biosciences, ImmunovaccineConsulting or Advisory Role: Genentech, Bayer, Merck, Juno Therapeutics, Roche, Teva, Rocket Medical, Seattle Genetics, Daiichi Sankyo, TakedaResearch Funding: Genentech, Roche, GlaxoSmithKline, Bayer, Pharmacyclics, Janssen, Rocket Medical, Seattle Genetics, Immunovaccine, IGM BiosciencesTravel, Accommodations, Expenses: Genentech, Roche, Seattle Genetics, Bayer Alison J. MoskowitzHonoraria: Seattle GeneticsConsulting or Advisory Role: Seattle Genetics, Takeda, Imbrium Therapeutics, Merck, Janpix, Kyowa Kirin International, miRagen, ADC Therapeutics, Bristol Myers SquibbResearch Funding: Incyte, Seattle Genetics, Merck, Bristol Myers Squibb, miRagen, ADC Therapeutics Ariela NoyConsulting or Advisory Role: MorphoSys, Janssen Biotech, Prime OncologyResearch Funding: Pharmacyclics, Rafael PharmaceuticalsTravel, Accommodations, Expenses: Pharmacyclics, Janssen Oncology Maria Lia PalombaStock and Other Ownership Interests: Seres TherapeuticsHonoraria: Merck, Celgene, Pharmacyclics, Flagship Biosciences, Novartis, Evelo Therapeutics, Jazz Pharmaceuticals, Therakos, Amgen, Seres TherapeuticsConsulting or Advisory Role: Merck, Celgene, Flagship Biosciences, Novartis, Evelo Therapeutics, Jazz Pharmaceuticals, Therakos, Amgen, Seres Therapeutics, Kite, Gilead Company, NovartisResearch Funding: Seres TherapeuticsPatents, Royalties, Other Intellectual Property: Intellectual Property Rights, Juno intellectual property rights David J. StrausConsulting or Advisory Role: Takeda, Seattle Genetics Anas YounesEmployment: AstraZenecaStock and Other Ownership Interests: AstraZenecaHonoraria: Merck, Roche, Takeda, Janssen, AbbVie, Curis, EpizymeConsulting or Advisory Role: Bio-Path Holdings Inc, Xynomic Pharma, Epizyme, Roche, Celgene, HCMResearch Funding: Janssen, Curis, Roche, Genentech, Merck, Bristol Myers Squibb, SyndaxOther Relationship: AstraZeneca Andrew D. ZelenetzHonoraria: NCCN, Clinical Care Options, Oncology Information Group, PER, PlexusConsulting or Advisory Role: Gilead Sciences, Amgen, Genentech/Roche, Celgene, AstraZeneca, DAVAOncology, MorphoSys, BeiGene, MEI Pharma, Vaniam Group, Verastem, Pharmacyclics, Karyopharm Therapeutics, Debiopharm Group, Seattle Genetics, Quant Health Ltd, Kite, Gilead Company, Curis, Coherus Biosciences, Juno/Celgene/Bristol Myers Squibb, Curio ScienceResearch Funding: Genentech/Roche, Gilead Sciences, MEI Pharma, BeiGene Craig H. MoskowitzConsulting or Advisory Role: Merck Sharp & Dohme, Molecular Templates, Takeda, AstraZeneca, IncyteResearch Funding: AstraZeneca, Merck Sharp & DohmeNo other potential conflicts of interest were reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu